Antithrombotic therapy for atrial fibrillation

Gregory Y H Lip ^1* and Christopher Boos ¹

¹ City Hospital, Birmingham, United Kingdom

^* To whom correspondence should be addressed. E-mail: g.y.h.lip{at}bham.ac.uk.

Accepted 14 August 2005

Abstract

Atrial fibrillation (AF) is a condition of increasing clinical and economic importance, being the most commonly encountered tachyarrhythmia in clinical practice.[1][2] Of note, AF currently accounts for 1% of all National Health Service expenditure in the United Kingdom.[3] The prevalence of AF is strongly age dependent, affecting 5% of individuals older than 65 years and nearly 10% of those aged >80 years.[4][5] Given the clear trend towards an increasingly aging population, the improved survival of patients of cardiovascular disease and the predominance of AF among older patients, the health care burden of AF is set to dramatically increase.[6] Indeed, hospitalization rates for AF have increased by 2-3 fold in recent years [7] and the prevalence of AF is projected to double over the next two generations.[3][4][5][6]

Keywords: aspirin, atrial fibrillation, warfarin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

WEB TOP 10
Heart 2006 92: 839. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Kaya, E. B., Tokgozoglu, L., Aytemir, K., Kocabas, U., Tulumen, E., Deveci, O. S., Kose, S., Kabakci, G., Nazli, N., Ozkutlu, H., Oto, A. (2008). Atrial myocardial deformation properties are temporarily reduced after cardioversion for atrial fibrillation and correlate well with left atrial appendage function. Eur J Echocardiogr 9: 472-477 [Abstract] [Full Text]  
• Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J. (2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S [Abstract] [Full Text]  
• Lip, G. Y H (2008). Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 336: 614-615 [Full Text]  
• Ruiz-Nodar, J. M., Marin, F., Hurtado, J. A., Valencia, J., Pinar, E., Pineda, J., Gimeno, J. R., Sogorb, F., Valdes, M., Lip, G. Y.H. (2008). Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation: Implications for Bleeding Risk and Prognosis. J Am Coll Cardiol 51: 818-825 [Abstract] [Full Text]  
• Choudhury, A., Freestone, B., Patel, J., Lip, G. Y. H. (2007). Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis?. Chest 132: 1913-1919 [Abstract] [Full Text]  
• Hohnloser, S. H., Pajitnev, D., Pogue, J., Healey, J. S., Pfeffer, M. A., Yusuf, S., Connolly, S. J., for the ACTIVE W Investigators, (2007). Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Substudy. J Am Coll Cardiol 50: 2156-2161 [Abstract] [Full Text]  
• Nutescu, E. A. (2007). ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. Am J Health Syst Pharm 64: 2281-2291 [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9: 1006-1023 [Abstract] [Full Text]  
• Mant, J., Fitzmaurice, D. A, Hobbs, F D R., Jowett, S., Murray, E. T, Holder, R., Davies, M., Lip, G. Y H (2007). Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ 335: 380-380 [Abstract] [Full Text]  
• Lip, G. Y. H. (2007). Coronary Artery Disease and Ischemic Stroke in Atrial Fibrillation. Chest 132: 8-10 [Full Text]  
• Lane, D. A., Lip, G. Y. H. (2007). Maintaining Therapeutic Anticoagulation: The Importance of Keeping "Within Range". Chest 131: 1277-1279 [Full Text]  
• Lip, G. Y H, Kakar, P., Watson, T. (2007). Atrial fibrillation--the growing epidemic. Heart 93: 542-543 [Abstract] [Full Text]  
• Varughese, G. I, Patel, J. V, Tomson, J., Lip, G. Y H (2007). Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation. Heart 93: 495-499 [Abstract] [Full Text]  
• Lip, G. Y.H., Patel, J. V., Hughes, E., Hart, R. G. (2007). High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis. Stroke 38: 1229-1237 [Abstract] [Full Text]  
• Lip, G. Y.H., Frison, L., Grind, M., on behalf of the SPORTIF Investigators, (2007). Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 28: 752-759 [Abstract] [Full Text]  
• Kalra, L, Lip, G Y H, on behalf of the Guideline Development Group for t, (2007). Antithrombotic treatment in atrial fibrillation. Heart 93: 39-44 [Full Text]  
• Lip, G. Y. H., Karpha, M. (2006). Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: The Need for Consensus and a Management Guideline. Chest 130: 1823-1827 [Abstract] [Full Text]  
• Kakar, P., Lane, D., Lip, G. Y. H. (2006). Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.. Chest 130: 1296-1299 [Full Text]  
• Lip, G. Y.H., Lane, D., Van Walraven, C., Hart, R. G. (2006). Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation. Stroke 37: 2294-2300 [Abstract] [Full Text]  
• Lip, G. Y.H., Watson, T., Shantsila, E. (2006). Anticoagulation for stroke prevention in atrial fibrillation: is gender important?. Eur Heart J 27: 1893-1894 [Full Text]  
• Lip, G. Y H, Tello-Montoliu, A. (2006). Management of atrial fibrillation.. Heart 92: 1177-1182 [Full Text]  
• Lip, G. Y.H. (2006). Aspirin for Prevention of Stroke in Atrial Fibrillation. Stroke 37: 1640-1640 [Full Text]  
• Lane, D. A., Boos, C. J., Lip, G. Y. H. (2006). Anticoagulation Control With Vitamin K Antagonists: How Well Are We Doing?. Chest 129: 1122-1124 [Full Text]